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The spread of antibiotic resistance among pathogenic bacteria
has become a major problem for the clinical management of
infectious diseases (Ghebremedhin et al., 2009). Such medical
health problems have encouraged many medicinal chemists
to search for novel antibacterial agents other than the analogs
of existing antibiotics (Dougherty and Friedberg, 2010; Bailey60921396.
(S.G. Abdel-Hamid).
y. Production and hosting by
Saud University.
lsevier
ND license.and Summers, 2008; Edwards and Biagini, 2006). Certain
quinazoline derivatives showed a remarkable activity against
the opportunistic infections of Pneumocystis carinii and
Toxoplasma gondii (Gangjee et al., 2008; Cody et al., 2004).
These microorganisms proved to be the clinical cause of death
in patients with immune-compromised diseases such as
acquired immune deﬁciency syndrome (AIDS). Recently, cer-
tain quinazoline derivatives are reported as an efﬁcient chemo-
sensitizer of antibiotic activity in Enterobacter aerogenes,
Klebsiella pneumoniae and Pseudomonas aeruginosa resistant
strains (Chevalier et al., 2010). More recently, some alkylami-
noquinazoline derivatives are reported to restore antibiotic
activity in Gram-negative resistant isolates (Mahamoud
et al., 2011).
Based on the aforementioned facts and as a continuation of
our previous efforts aiming to locate new active quinazoline-
based antimicrobial agents with enhanced potency, reduced tox-
icity and low cost, a new series of 6-iodoquinazoline derivatives
were synthesized and screened (Aziza et al., 1996; Allimuny
et al., 1996; Ghorab et al., 1995). In this work, the quinazoline
320 A.M. Alafeefy et al.analogs were designed to contain some functional groups that
are believed to contribute to the antimicrobial activity such as
–NHCOCH3, –SCH2CONH2 in addition to a collection of fused
or connected heterocycles to the quinazoline ring such as benz-
imidazole, 1,3-thiazolidine, 1,2,4-triazole. The new synthesized
compounds were screened against Gram negative Escherichia
coli, Gram positive bacteria (Staphylococcus aureus, Bacillus
subtilis) and pathogenic fungi (Saccharomyces cerevisiae, Can-
dida albicans).2. Experimental
All melting points were recorded in open capillaries and were
uncorrected. Microanalysis was conducted on a Heraeus
instrument, results were within ±0.4% of the theoretical val-
ues, thin layer chromatography was performed on Merck
5 · 10 cm plates, pre-coated with silica gel GF254 using short
wavelength UV light for visualization (EtOAc, hexane 2:1).
All ﬁne chemicals and reagents were purchased from Aldrich
chemical Co., USA. 1H NMR spectrum was recorded on a
Varian Gemini 200 MHz spectrophotometer; chemical shifts
were in r (ppm) values downﬁeld from tetramethylsilane as
the internal standard. The following organisms were used in
the antimicrobial screening. E. coli ATCC 10536, S. aureus
ATCC 06538, B. subtilis ATCC 6633, S. cerevisiae ATCC
9763 and C. albicans ATCC 1023.
The starting materials 6-iodo-2-thienyl-1,3-benzoxazin-
4(3H)-one (1), 6-iodo-2-thienylquinazolin-4(3H)-one,
3-amino-6-iodo-2-thienylquinazolin-4(3H)-one (7), 6-iodo-2-
thienyl-3,4-dihydroquinazolin-4-one (20) and 6-iodo-2-thie-
nyl-3,4-dihydroquinazolin-4-thione (22) were synthesized
according to reported procedures.
2.1. 2-Thienyl-6-iodo-3-(4-bromophenyl)-quinazoline-4(3H)-
one (2) (Al-Obaid et al., 2009)
A mixture of compound (1, 3.55 g, 0.01 mol) and 4-bromoani-
line (2.5 g, 0.015 mol) in dry pyridine (15 ml) was heated under
reﬂux for 24 h. The reaction mixture was cooled, treated with
cold hydrochloric acid. The separated solid was ﬁltered, washed
with water, dried and crystallized from ethanol Table 1. 1H
NMR (DMSO-d6), 2: d 7.26 (t, 1H, J= 4-Hz, thiophene-H),
7.70 (d, 1H, J= 0.5-Hz, thiophene), 7.86–7.88 (dd, 1H,
J= 41.5, 8.5-Hz, quinazoline-H), 7.90 (d, 1H, J= 4.0-Hz, thi-
ophene-H), 8.00–8.60 (m, 6H, Ar-H).
2.2. 2-(2-Thienyl)-6-iodo-3-[-2-substituted phenyl]-3H-
quinazoline-4-one (3a,b) (Abdel-Hamid, 2001)
A mixture of 4H-3,1-benzoxazin-4-one derivative (1, 3.55
g, 0.01 mol) and the appropriate aromatic amine (0.015 mol)
in dry pyridine (15 ml) was heated under reﬂux for 18 h. The sol-
vent was removed under reduced pressure. The obtained solid
was ﬁltered, washed with diluted HCl and crystallized from an
appropriate solvent Table 1. 1H NMR (DMSO-d6), 3a: d 5.00
(s, 2H, NH2), 6.90–7.80 (m, 7H, Ar-H), 7.90 (d, 1H,
J= 4.0 Hz, thiophene-H), 8.15 (d, 1H, J= 1.50-Hz,
quinazoline-H), 8.34 (d, 1H, J= 8.5 Hz, quinazoline-H). Com-
pound 3b: d 3.69 (s, 3H, OCH3), 6.85–7.75 (m, 6H, Ar-H), 7.86–
7.88 (dd, 1H, J= 1.5, J= 8.5 Hz, quinazoline-H), 7.92 (d, 1H,J= 4.0 Hz, thiophene-H), 8.15 (d, 1H, J= 1.5 Hz, quinazo-
line-H), 8.35 (d, 1H, J= 8.5 Hz, quinazoline-H).
2.3. 6-(2-Thienyl)-2-iodo-benzimidazo[1,2-c]-quinazoline (4)
(Abdel-Hamid, 1997)
A mixture of compound (1, 3.55 g, 0.01 mol) and o-phenylene-
diamine (1.08, 0.01 mol) and fused sodium acetate in glacial
acetic acid (15 ml) was heated under reﬂux for 24 h. The mix-
ture was cooled and the obtained solid was ﬁltered, washed
with water, dried and crystallized from ethanol Table 1. 1H
NMR (DMSO-d6), 4: d 7.26–7.83 (m, 7H, Ar-H), 7.91 (d,
1H, J= 4.0 Hz, thiophene-H), 8.15 (d, 1H, J= 1.50-Hz, qui-
nazoline-H), 8.34 (d, 1H, J= 8.5 Hz, quinazoline-H).
2.4. 2-(2-Thienyl carbonylamino)-5-iodo-N-[isobutyl]-
benzamide (5) (Abdel-Hamid, 1999)
A mixture of 4H-3,1-benzoxazin-4-one derivative (1, 3.55 g,
0.01 mol) and isobutyl amine (2.19 g, 0.003 mol) in dry pyridine
(15 ml) was heated under reﬂux for 18 h. The solvent was re-
moved under reduced pressure. The obtained solid was ﬁltered,
washed with diluted HCl and crystallized from glacial acetic
acid Table 1. 1H NMR (DMSO-d6), 5: d 1.1 (d, 6H, J= 8 Hz
(CH3)2CH–), 2.3 (m, 1H, (CH3)2CH–CH2), 3.16 (d, 2H,
J= 8.00 Hz, N–CH2CH(CH3)2), 7.27 (t, 1H, J= 4.00-Hz, thi-
ophene-H), 7.71 (d, 1H, J= 0.5 Hz, thiophene-H), 7.87–7.89
(dd, 1H, J= 1.5, J= 8.5 Hz, Ar-H), 7.92 (d, 1H,
J= 4.0 Hz, thiophene-H), 8.16 (d, 1H, J= 1.5 Hz, Ar-H),
8.32 (d, 1H, J= 8.5 Hz, Ar-H), 9.3 (s, 1H, CONH–CH2),
12.36 (s, 1H, (Ph–NH–CO).
2.5. 2-(2-Thienyl)-6-iodo-3-methyl-quinazoline-4-one (6)
A mixture of 4H-3,1-benzoxazin-4-one derivative
(1, 3.55 g, 0.01 mol) and N-methyl-formamide (30 ml) was
heated under reﬂux for 6 h., on cooling, the separated solid
was ﬁltered, washed with water and crystallized from glacial
acetic acid Table 1. 1H NMR (DMSO-d6), 6: d 2.61 (s, 3H,
N–CH3), 7.23 (d, 1H, J= 4.00 Hz, thiophene-H), 7.73 (d,
1H, J= 0.5 Hz, thiophene-H), 7.86–7.88 (dd, 1H, J= 8.5,
J= 1.50-Hz, quinazoline-H), 7.95 (d, 1H, J= 0.5 Hz, thio-
phene-H), 8.14 (d, 1H, J= 1.5 Hz, quinazoline-H), 8.34 (d,
1H, J= 8.5 Hz, quinazoline-H).
2.6. 9-Iodo-5-(2-thieno)-3H-2-thioxo-1,2,4-triazolo-[2,3-
c]quinazoline-4-one (8)
An equimolar amount of 4H-3,1-benzoxazin-4-one derivative
(1, 3.55 g, 0.01 mol) and thiosemicarbazide (0.9 g, 30 ml) was
fused together at 190 C in an oil bath for 1 h, on cooling,
the solid mass was dissolved in boiling glacial acetic acid
(50 ml) and ﬁltered, the ﬁltrate was concentrated up to
(10 ml) in vacuo and cooled, the resulting solid ﬁltered,
washed with water and crystallized from glacial acetic acid
to afford 8 Table 1. 1H NMR (DMSO-d6), 8: d 7.26 (t,
1H, J= 4.00 Hz, thiophene-H), 7.70 (d, 1H, J= 0.5 Hz, thi-
ophene-H), 7.88–7.89 (dd, 1H, J= 8.5, J= 1.50 Hz, Ar-H),
7.91 (d, 1H, J= 4.0 Hz, thiophene-H), 8.14 (d, 1H,
J= 1.5 Hz, Ar-H), 8.33 (d, 1H, J= 8.5 Hz, Ar-H), 12.41
(s, 1H, CH–N).
Table 1 The physicochemical properties of new synthesized compounds.
No. Compound Solvent of crystallization Melting point Yield (%) Molecular formula
1 2 Ethanol 237–239 71 C18H10BrIN2OS
2 3a Dioxane 270–272 65 C18H12IN3OS
3 3b Acetic acid 175–177 73 C19H13IN2O2S
4 4 Ethanol 221–223 66 C18H10IN3S
5 5 Acetic acid 141–143 76 C16H17IN2O2S
6 6 Acetic acid ±300 74 C13H9IN2OS
7 8 Acetic acid ±300 64 C13H7IN4S2
8 9 Acetic acid 230–232 73 C17H10IN3OS2
9 10 Acetic acid 220–222 77 C18H11IN4OS
10 11 Acetic acid 230–232 81 C21H14IN3OS
11 12 Ethanol ±300 75 C19H12IN5OS
12 13 Ethanol 280–282 69 C24H17IN4OS2
13 14 Ethanol 210–212 43 C19H12IN3O2S3
14 15 Ethanol 200–201 50 C21H14IN3O2S
15 16 Acetic acid 223–225 70 C14H10IN3O2S
16 18 Acetic acid 209–211 65 C14H9ClIN3O2S
17 21 Ethanol 85–87 77 C16H15IN2OS
18 22 Ethanol 225–226 63 C12H7IN2S2
19 23 Dioxane 260–262 72 C14H12IN3OS2
20 24 Acetic acid ±300 63 C20H15IN4OS
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dihydroquinazoline-4-ones (9–11)
A mixture of 2-(2-thienyl)-3-amino-6-Iodo-3,4-dihydroquinaz-
oline-6-one 7 (3.69 g, 0.01 mol) and the appropriate aldehyde
(0.015 mol) in glacial acetic acid (50 ml) was heated under re-
ﬂux for 24 h., on cooling, the separated solid was ﬁltered,
washed with water and crystallized from glacial acetic acid
to give 9–11 Table 1. 1H NMR (DMSO-d6), 9: d 7.21–7.9
(m, 7H, thiophene-H and quinazoline-H), 8.15 (d, 1H,
J= 1.5 Hz, quinazoline-H), 8.34 (d, 1H, J= 8.5 Hz, quinaz-
oline-H), 9.23 (s, 1H, –CH‚N). Compound 10: d 7.27–8.06
(m, 7H, thiophene-H, pyridine-H and quinazoline-H), d 8.15
(d, 1H, J= 1.5 Hz, quinazoline-H), d 8.35 (d, 1H,
J= 8.5 Hz, quinazoline-H), d 8.71 (d, 1H, J= 6 Hz, pyri-
dine-H), d 9.21 (s, 1H, CH‚N). Compound 11: d 5.73 (d,
1H, J= 5 Hz, oleﬁnic-H), d 6.53 (d, 1H, J= 5 Hz, oleﬁnic-
H), d 7.27–7.78 (m, 7H, Ar-H and thiophene-H), d 7.87–7.89
(dd, 1H, J= 8.5 Hz, 1.5 Hz, quinazoline-H), d 7.93 (d, 1H,
J= 4 Hz, thiophene-H), d 8.15 (d, 1H, J= 1.5 Hz, quinazo-
line-H), d 8.35 (d, 1H, J= 4.0 Hz, quinazoline-H), d 9.21 (s,
1H, –CH‚N).
2.8. 2-(6-Iodo-4-oxo-2-[thienyl] quinazolin-3-(4H)-ylamino)-
2-(pyridin-2-yl)-acetonitrile (12)
A mixture of compound (10, 0.01 mol) and potassium cya-
nide (0.01 mol in 5 ml H2O) in glacial acetic acid (30 ml)
was reﬂuxed for 4 h, the reaction mixture was cooled and di-
luted with 20 ml cold water, the separated solid was ﬁltered,
washed with water and crystallized from ethanol to afford 12
Table 1. 1H NMR (DMSO-d6), 12: d 4.1 (s, 1H, N–NH–
CH(Pyridyl)–CN), d 5.21 (s, 1H, NH–CH(Ph)–CN), d 7.27–
7.92 (m, 7H, pyridine-H, thiophene-H and quinazoline-H),
d 8.14 (d, 1H, J= 1.5 Hz, quinazoline-H), d 8.35 (d, 1H,
J= 8.5 Hz, quinazoline-H), d 8.72 (d, 1H, J= 6 Hz, pyri-
dine-H).2.9. 3-[1-(2-Pyridinyl)-1-(phenylthiomethyl)amino]-2-
(thienyl)-6-iodo-4-(3H)quinazoline (13)
An equimolar amount of compound (10, 12) (29 g, 0.01 mol)
and thiophenol (0.55 g, 0.05 mol) was fused together in an oil
bath at 200 C for 1 h, on cooling the solid mass was dissolved
in boiling ethanol (50 ml) and ﬁltered. The ﬁltrate was concen-
trated to half its volume, the separated solid was ﬁltered and
crystallized from ethanol to give 13 Table 1. 1H NMR
(DMSO-d6), 13: d 4.4 (s, 1H, NH–), d 5.1 (s, 1H, CH–S), d
7.18–8 (m, 12H, pyridine-H, thiophene-H and Ar-H), d 8.15
(d, 1H, J= 1.5 Hz, quinazoline-H), d 8.35 (d, 1H, J= 8 Hz,
quinazoline-H), d 8.72 (d, 1H, J= 6 Hz, pyridine-H).
2.10. 2-(2-Thienyl)-3-[2-(thienyl)-4-oxo-1,3-thiazolidin-3-yl]-
6-iodo-3,4-dihydroquinazolin-4-one (14)
A mixture of (9, 2.32 g, 0.005 mol) and thioglycolic acid
(0.9 g, 0.01 mol) and anhydrous sodium chloride (1 g) in dry
toluene (10 ml) was heated to reﬂux for 18 h. The reaction mix-
ture was then ﬁltered while hot. The clear ﬁltrate was evapo-
rated under reduced pressure and the obtained solid was
crystallized from ethanol to afford 14 Table 1. 1H NMR
(DMSO-d6): d 3.72 (s, 2H, CO–CH2–S), d 6.15 (s, 1H, S–
CH–), d 7.1–7.96 (m, 7H, thiophene-H and quinazoline-H), d
8.13 (d, 1H, J= 1.5 Hz, quinazoline-H), d 8.35 (d, 1H,
J= 8 Hz, quinazoline-H).
2.11. 2-(2-Thieno)-3-(cinnamoylamino)-6-iodo-4-oxo-3H-
quinazoline (15)
A mixture of 2-(2-thienyl)-6-iodo-3-amino-quinazolin-4-one
(7, 1.85 g, 0.005 mol) and cinnamoyl chloride (0.83 g,
0.005 mol) in dry dimethyl formamide (25 ml) was heated under
reﬂux for 1 h. The reaction mixture was cooled, poured into ice
and stirred. The produced solid was ﬁltered off washed with
water, dried and crystallized from ethanol to afford 15 Table
Table 2 Antimicrobial screening results of the tested compounds at 1 mg/ml concentration.
No. Compound no. E. coli S. aureus B. subitilis S. cerevisia C. albicans
1 1   +  +
2 2  +   +
3 3a  ++ ++ ++ +
4 3b  + + + ++
5 4 +++ ++ ++ +++ +++
6 5  +  + 
7 6 +   + 
8 7 + + +  +
9 8 ++ ++ +++ +++ +++
10 9 +++  ++  +
11 10  +   +
12 11 + ++ + ++ +
13 12 +   + 
14 13 ++  ++ + +
15 14 ++ +++ +++ ++ ++
16 15 ++ ++  ++ 
17 16 +++  + + +++
18 18 + +  ++ 
19 20 + ++ ++  
20 21 +  +  
21 22 +++ ++ ++  
22 23 + ++  + +
23 24 ++ ++ ++ ++ ++
24 Ampicillin +++ +++ +++ NT NT
25 Streptomycin +++ +++ +++ NT NT
26 Nystatin NT NT NT ++ ++
() Inactive (inhibition zone < 10 mm), (+) moderate activity (inhibition zone 10–15 mm), (++) active (inhibition zone 15–20 mm), (+++)
remarkable activity (inhibition zone > 20 mm), (NT) = not tested.
322 A.M. Alafeefy et al.1. 1H NMR (DMSO-d6), 15: d 6.8–7.98 (m, 11H, Ar-H), d 8.15
(d, 1H, J= 1.5 Hz, quinazoline-H), d 8.35 (d, 1H, J= 8.5 Hz,
quinazoline-H), d 10.1 (bs, 1H, NH–CO).
2.12. 2-(2-Thieno)-3-(acetylamino) -6-iodo-4-oxo-3H-
quinazoline (16)
A mixture of 2-(2-thienyl)-6-iodo-3-amino-quinazolin-4-one
(7, 1.85 g, 0.005 mol) and acetyl chloride (1 g, 0.02 mol) in
dry dimethyl formamide (10 ml) was stirred at room tempera-
ture for 1 h. The reaction mixture was concentrated under va-
cuo and the resulting solid was crystallized from methanol to
afford 16 Table 1. 1H NMR (DMSO-d6): d 2.7 (s, 3H, –
CH3), d 7.26 (t, 1H, J= 4 Hz, thiophene-H), d 7.7 (d, 1H,
J= 0.5 Hz, thiophene-H), d 7.86–7.88 (dd, 1H, J= 1.5 Hz,
J= 8.5 Hz, Ar-H), d 7.92 (d, 1H, J= 4 Hz, thiophene-H), d
8.15 (d, 1H, J= 1.5 Hz, Ar-H), d 8.35 (d, 1H, J= 8 Hz, Ar-
H), d 11.2 (bs, 1H, N–NH–CO).
2.13. 2-(2-Thieno) -6-iodo-3-amino-3,4-dihydroquinazolin-4-one
(7)
A mixture of compound (16, 2.05 g, 0.005 mol) and hydrazine
hydrate (1 g, 0.01 mol) in n-butanol (10 ml) was heated under
reﬂux for 18 h. The reaction mixture was concentrated, cooled
and the separated solid was crystallized out from ethanol to af-
ford 7Table 1. 1HNMR (DMSO-d6): d 5.6–5.7 (bs, 2H, NH2), d
7.27 (t, 1H, J= 4 Hz, thiophene-H), d 7.73 (d, 1H, J= 0.5 Hz,
thiophene-H), d 7.85–7.87 (dd, 1H, J= 1.5 Hz, J= 8.5 Hz,
quinazoline-H), d 7.92 (d, 1H, J= 4 Hz, thiophene-H), d 8.14(d, 1H, J= 1.5 Hz, quinazoline-H), d 8.32 (d, 1H, J= 8.5 Hz,
quinazoline-H).
2.14. N-(6-Iodo-2-(2-thieno)-4(3H)-quinazolinon-3-yl)-2-
chloroacetamide (18)
Amixture of compound (7, 1.85 g, 0.005 mol) and chloroacetyl
chloride (0.85 g, 0.0075 mol) was heated under reﬂux in dry di-
methyl formamide (15 ml) for 3 h. The reaction mixture was
concentrated to half its volume, cooled, treated with ice-cold
water (10 ml), the resulting solid was ﬁltered, washed with
water, dried and crystallized from ethanol to afford 18 Table
1. 1H NMR (DMSO-d6), 7: d 4.23 (s, 2H, NH–CO–CH2–Cl),
d 7.27 (t, 1H, J= 4 Hz, thiophene-H), d 7.73 (d, 1H,
J= 0.5 Hz, thiophene-H), d 7.85–7.87 (dd, 1H, J= 1.5 Hz,
J= 8.5 Hz, Ar-H), d 7.92 (d, 1H, J= 4.0 Hz, thiophene-H),
d 8.15 (d, 1H, J= 1.5 Hz, Ar-H), d 8.35 (d, 1H, J= 8.5 Hz,
Ar-H), 9.12 (s, 1H, N–NH–CO–CH2–Cl).
2.15. 2-(2-Thienyl)-6-iodo-3, 4-dihydroquinazolin-4-one (20)
A mixture of compound (18, 0.95 g, 0.002 mol) and anhydrous
ammonium acetate (0.77 g, 0.01 mol) in glacial acetic acid
(10 ml) was heated under reﬂux for 18 h. The reaction mixture
was concentrated to half its volume, the separated solid was ﬁl-
tered, washed with water and crystallized from acetic acid to
afford 20 Table 1. 1H NMR (DMSO-d6), 20: d 7.25 (t, 1H,
J= 4 Hz, thiophene-H), d 7.71 (d, 1H, J= 0.5 Hz, thio-
phene-H), d 7.87–7.89 (dd, 1H, J= 1.5 Hz, J= 8.5 Hz,
Ar-H), d 7.91 (d, 1H, J= 4 Hz, thiophene-H), d 8.15 (d, 1H,
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(bs, H, –NH).
2.16. 2-(2-Thieno)-4-n-butoxy-6-iodo-quinazoline (21)
A mixture of compound (20, 1.77 g, 0.005 mol), n-butyl bro-
mide (0.0075 mol) and anhydrous potassium carbonate (1 g)
in dry acetone (25 ml) was heated under reﬂux for 8 h, the reac-
tion mixture was then ﬁltered while hot. The ﬁltrate was evapo-
rated under vacuum and the separated solid was washed with
water and crystallized from ethanol to give 21 Table 1. 1H
NMR (DMSO-d6), 21: d 0.96 (t, 3H, J= 7.0 Hz, O–
CH2CH2CH2CH3), d 1.33–1.46 (m, 4H, J= 7.0 Hz, O–
CH2CH2CH2CH3), d 3.95–4.0 (t, 2H, J= 7.0 Hz, O–CH2CH2CH2CH3), d 7.27 (t, 1H, J= 4.0 Hz, thiophene-H), d 7.70
(d, 1H, J= 0.5 Hz, thiophene-H), d 7.86–7.88 (dd, 1H,
J= 1.5 Hz, J= 8.5 Hz, quinazoline-H), d 7.91 (d, 1H,
J= 4.0 Hz, thiophene-H), d 8.14 (d, 1H, J= 1.5 Hz, quinazo-
line-H), d 8.34 (d, 1H, J= 8.5 Hz, quinazoline-H).
2.17. 2-(2-Thienyl)-4-(2-benzimidazolylmethyloxy)-6-iodo-
quinazoline (24)
A mixture of compound (20, 1.77 g, 0.005 mol) anhydrous
potassium carbonate (2 g) in dry acetone (30 ml), anhydrous
potassium carbonate (2 g) was added followed by the addition
of 2-chloromethyl benzimidazole (1 g, 0.006 mol). The reaction
mixture was heated under reﬂux for 48 h. The solvent was re-
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324 A.M. Alafeefy et al.moved in vacuo and the obtained solid was crystallized from
ethanol to give 24 Table 1. 1H NMR (DMSO-d6), 24: d 4.6
(s, 2H, O–CH2-hetero), d 7.26–7.92 (m, 9H, Ar-H, benzimid-
azole-H, NH, thiophene-H, and quinazoline-H), d 8.15 (d,
1H, J= 1.5 Hz, quinazoline-H), d 8.35 (d, 1H, J= 8.5 Hz,
quinazoline-H).
2.18. 2-(6-Iodo-2-(thien-2-yl)-6-quinazolin-4-ylthio)-acetamide
(23)
To a solution of compound (22, 1.85 g, 0.005 mol) in dry ace-
tone (30 ml), anhydrous potassium carbonate (2 g) was added
followed by the addition of 2-chloroacetamide (0.7 g,
0.0075 mol). The reaction mixture was heated under reﬂux for
20 h, ﬁltered while hot and the ﬁltrate was evaporated in vacuo
to give the crude product which was crystallized from ethanol to
afford 23 Table 1. 1H NMR (DMSO-d6), 23: 4.62 (s, 2H,
S–CH2–CO), d 7.24 (t, 1H, J= 4.0 Hz, thiophene-H), d 7.70
(d, 1H, J= 0.5 Hz, thiophene-H), d 7.86–7.88 (dd, 1H,
J= 1.5 Hz, J= 8.5 Hz, quinazoline-H), d 7.91 (d, 1H,
J= 4 Hz, thiophene-H), d 8.15 (d, 1H, J= 1.5 Hz,quinazoline-H), d 8.34 (d, 1H, J= 8.5 Hz, quinazoline-H), d
12.3 (bs, 2H, –NH2).
3. Antimicrobial testing
Nutrient agar plates were seeded using 0.1 of overnight cul-
tures. Cylindrical plugs were removed from the agar plates
using a sterile cork borer and 100 lL of the tested compound
(1 mg/ml DMSO) was added to the well in triplicates. A blank
solvent was used as control. Plates inoculated with the tested
bacteria were incubated at 37 C, while those of the fungi were
incubated at 30 C. The results were taken after 24 h of incu-
bation and were recorded as the average diameter of inhibition
zone in mm.
4. Antimicrobial screening
All the new synthesized compounds were subjected to antimi-
crobial screening by in vitro cup-plate technique (Mahamoud
et al., 2011) using ampicillin, streptomycin and nystatin as
the positive controls. Compounds 4, 9, 16 and 22 showed
Synthesis of some new substituted iodoquinazoline derivatives and their antimicrobial screening 325remarkable activity towards the gram negative bacteria E. coli.
The Gram positive bacteria S. aureus and B. subitilis proved to
be sensitive toward compounds 3a, 4, 8, 14, 20, 22 and 24.
Compounds 4, 8, 14 and 24 showed very good activity to-
ward the tested fungal strains, S. Cerevsiae and C. albicans.
Compounds 4, 8, 14 and 24 proved to be the most active
broad spectrum antimicrobial agents in this study Table 2. A
close check of the structures of the active compounds revealed
that the remarkable antimicrobial activity was conﬁned to the
compounds that possess either fused or connected heterocycles
to a quinazoline skeleton e.g. 1,2,4-triazino (8), or benzimidazo
(4) ring, also attachment of benzimidazole and 1,3-thiazolidi-
none to quinazoline nucleus increased remarkably the antimi-
crobial activity.
In conclusion the present study revealed that the heterocy-
clic system 1,2,4-triazino[3,4-c]quinazoline and benzimi-
dazo[1,2-c]quinazoline, in addition to the quinazoline ring
bearing either benzimidazole or 1,3-thiazolidinone moieties
could be useful as a template for future development through
modiﬁcation or derivatization to design a more potent antimi-
crobial agent.
5. Results and discussion
The strategy to synthesize the target compounds 1–24, is
shown in Schemes 1–3. The starting material 2-thienyl-4-oxo-
6iodo-benzoxazine (1) was allowed to react with a variety of
substituted aromatic amines and isobutylamine to furnish
compounds2, 3a, 3b and 5, respectively. Fusion of the benzox-
azine derivative with o-phenylenediamine at a high tempera-
ture gave the cyclized benzimidazo-[1,2-c]quinazoline. Boiling
compound 2 with n-methyl formamide or hydrazine hydrate
affords compounds 6 and 7, respectively. Reaction of thiosem-
icarbazide with the benzoxazine (1) in the least amount of boil-
ing glacial acetic acid afforded the triazolo derivative (8). The
3-amino derivative (7) was reacted with different heterocyclic
aldehydes and or cinnamaldehyde in boiling glacial acetic acid
to give compounds 9–11 respectively. Subjecting the com-
pound (10) to the action of HCN in glacial acetic acid and/
or thiophenol (by fusion) afforded the additional derivatives
(12, 13). Compound (9) was reacted with mercapto acetic acid
(in benzene to produce thiazolidene-4-one derivative (14).
Reaction of cinnamaldehyde chloride with compound 7 affor-
ded compound (15). The 3-amino derivative (7b) was reacted
with acetyl chloride to give the acetyl derivative (16) which
upon treatment with hydrazine hydrate in ethanol failed to
form the fused heterocyclic analog (17) but gives instead the
3-amino derivative (7). The latter compound was boiled with
phosphorus pentasulphide in pyridine to give the correspond-
ing thioxo analog (22). Compound (20) was subjected to alkyl-
ation by 2-chloromethyl benzoimidazole to give compounds
21 and 24, respectively. Compound (21) was reacted with bro-
moacetamide in acetone containing anhydrous potassium car-
bonate to afford the analog (23).References
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